H. Lundbeck On 22 April 2008, the Annual General Meeting of H. Lundbeck A/S resolved to reduce the company's share capital by a nominal amount of DKK 51,966,745 by reducing the company's holding of treasury shares.
The resolution was announced in the electronic information system of the Danish Commerce and Companies Agency on 28 April 2008, and the statutory notice period has now expired with no claims received.
Accordingly, the reduction of the company's share capital was registered with the Danish Commerce and Companies Agency today.
Following the reduction of capital, the nominal share capital of H. Lundbeck A/S as of 31 August 2008 amounts to 984,431,410 divided into 196,886,282 shares of DKK 5 each and 196,886,282 votes.
The content of this release will have no influence on the Lundbeck Group's financial result for 2008.
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Jens Harder Højbjerg Director Media Relations Manager +45 36 43 30 79 +45 36 43 28 33
Palle Holm Olesen Head of Investor Relations +45 36 43 24 26
Release No 350 - 31 July 2008
About Lundbeck H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. In 2007, the company's revenue was DKK 11 billion (approximately EUR 1.6 billion or USD 2.0 billion). The number of employees is approx. 5,300 globally. For more information, please visit www.lundbeck.com.
H. Lundbeck
http://www.lundbeck.com
ISIN: DK0010287234
Stock Identifier: XCSE.LUN
The resolution was announced in the electronic information system of the Danish Commerce and Companies Agency on 28 April 2008, and the statutory notice period has now expired with no claims received.
Accordingly, the reduction of the company's share capital was registered with the Danish Commerce and Companies Agency today.
Following the reduction of capital, the nominal share capital of H. Lundbeck A/S as of 31 August 2008 amounts to 984,431,410 divided into 196,886,282 shares of DKK 5 each and 196,886,282 votes.
The content of this release will have no influence on the Lundbeck Group's financial result for 2008.
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Jens Harder Højbjerg Director Media Relations Manager +45 36 43 30 79 +45 36 43 28 33
Palle Holm Olesen Head of Investor Relations +45 36 43 24 26
Release No 350 - 31 July 2008
About Lundbeck H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. In 2007, the company's revenue was DKK 11 billion (approximately EUR 1.6 billion or USD 2.0 billion). The number of employees is approx. 5,300 globally. For more information, please visit www.lundbeck.com.
H. Lundbeck
http://www.lundbeck.com
ISIN: DK0010287234
Stock Identifier: XCSE.LUN
| Tweet |
 |
Related Companies |
>>> H. Lundbeck |
| |
Related Industry Topics: |
European Finance News | |
| |
This Page Viewed: (Last 30 Days: 10) (Since Published: 3530) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
Upcoming WebCasts
 | Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
 | Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
 | Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
 | Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
Companies in the News
Mobile Video TV
|
||
|
||
